Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine
- PMID: 6107263
- PMCID: PMC1419886
- DOI: 10.1136/gut.21.7.632
Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine
Abstract
Suppositories of sulphapyridine, 5-aminosalicylic acid, and placebo were used in 45 patients with idiopathic proctitis to determine the active part of sulphasalazine. Each patient used one of the suppositories twice daily for four weeks in a double-blind controlled trial. Complete clinical remission with normal rectal mucosa on sigmoidoscopy occurred in 60% of patients given 5-aminosalicylic acid, but in only 13% and 27% of those given sulphapyridine and placebo respectively. Twelve patients were included twice. In eight of these patients 5-aminosalicylic acid was given one time and sulphapyridine (two patients) or placebo (six patients) another time. Clinical remission occurred in each patient with 5-aminosalicylic acid, but in only one patient during other therapy. The results suggest that 5-aminosalicylic acid is the active therapeutic moiety of sulphasalazine.
Similar articles
-
Active therapeutic moiety of sulphasalazine.Lancet. 1978 Feb 4;1(8058):277. doi: 10.1016/s0140-6736(78)90524-x. Lancet. 1978. PMID: 74700 Clinical Trial. No abstract available.
-
5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?Drugs. 1986;32 Suppl 1:27-34. doi: 10.2165/00003495-198600321-00006. Drugs. 1986. PMID: 2877851
-
Which component of sulphasalazine is active in rheumatoid arthritis?Br Med J (Clin Res Ed). 1985 May 25;290(6481):1535-8. doi: 10.1136/bmj.290.6481.1535. Br Med J (Clin Res Ed). 1985. PMID: 2860942 Free PMC article. Clinical Trial.
-
Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?Br J Rheumatol. 1995 Nov;34 Suppl 2:16-9. Br J Rheumatol. 1995. PMID: 8535642 Review.
-
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001. Clin Pharmacokinet. 1985. PMID: 2864155 Review.
Cited by
-
Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.Gut. 1989 May;30(5):675-9. doi: 10.1136/gut.30.5.675. Gut. 1989. PMID: 2567266 Free PMC article. Clinical Trial.
-
Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.Br Med J (Clin Res Ed). 1981 May 16;282(6276):1571-3. doi: 10.1136/bmj.282.6276.1571. Br Med J (Clin Res Ed). 1981. PMID: 6113021 Free PMC article. Clinical Trial.
-
Olsalazine in maintenance of clinical remission in patients with ulcerative colitis.Dig Dis Sci. 1993 Oct;38(10):1837-42. doi: 10.1007/BF01296107. Dig Dis Sci. 1993. PMID: 8404404 Clinical Trial.
-
Is N-acetylation of 5-aminosalicylic acid reversible in man?Br J Clin Pharmacol. 1984 Oct;18(4):612-5. doi: 10.1111/j.1365-2125.1984.tb02513.x. Br J Clin Pharmacol. 1984. PMID: 6487501 Free PMC article.
-
Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils.Gut. 1989 Nov;30(11):1581-7. doi: 10.1136/gut.30.11.1581. Gut. 1989. PMID: 2574700 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources